HC Wainwright Has Bearish Estimate for Evommune Q1 Earnings

Evommune, Inc. (NYSE:EVMN) – Investment analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Evommune in a research note issued to investors on Wednesday, March 18th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.83) per share for the quarter, down from their previous forecast of ($0.36). HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. HC Wainwright also issued estimates for Evommune’s Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($3.00) EPS.

EVMN has been the subject of a number of other reports. Oppenheimer assumed coverage on shares of Evommune in a research note on Thursday, January 22nd. They set an “outperform” rating and a $42.00 target price for the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $54.00 price target on shares of Evommune in a research note on Wednesday, February 18th. Zacks Research upgraded shares of Evommune to a “hold” rating in a report on Tuesday, December 2nd. Clear Str raised shares of Evommune to a “strong-buy” rating in a research report on Tuesday. Finally, Evercore restated an “outperform” rating and issued a $55.00 target price on shares of Evommune in a research note on Tuesday, February 10th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $47.17.

Evommune Stock Down 0.9%

Shares of Evommune stock opened at $23.35 on Friday. The firm has a fifty day simple moving average of $23.32. Evommune has a 52 week low of $13.89 and a 52 week high of $33.20. The company has a market cap of $840.99 million and a P/E ratio of -2.89.

Evommune (NYSE:EVMN) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.61).

Hedge Funds Weigh In On Evommune

Several institutional investors have recently made changes to their positions in EVMN. China Universal Asset Management Co. Ltd. bought a new stake in shares of Evommune in the fourth quarter valued at about $34,000. The Manufacturers Life Insurance Company bought a new position in Evommune during the 4th quarter worth about $179,000. XTX Topco Ltd purchased a new position in Evommune during the 4th quarter valued at about $321,000. Oxford Asset Management LLP bought a new stake in shares of Evommune in the 4th quarter valued at about $335,000. Finally, State Street Corp bought a new stake in shares of Evommune in the 4th quarter valued at about $539,000.

Key Headlines Impacting Evommune

Here are the key news stories impacting Evommune this week:

• Positive Sentiment: Clear Street / Clear Str initiated coverage / upgraded Evommune with a buy / strong-buy stance, which can attract demand from momentum and growth-focused funds. Clear Street initiates coverage of Evommune (EVMN) with buy recommendation
• Neutral Sentiment: A market/industry article about Planet Labs was also logged in the feed but is unrelated to Evommune’s fundamentals or near-term catalysts. Traders are unlikely to move EVMN based on that piece. Planet Labs (NYSE:PL) Revenue Beats, Lags NYSE Index on Profit
• Negative Sentiment: HC Wainwright sharply cut its quarterly and full-year EPS forecasts for 2026–2027 (FY2026 EPS from prior -$1.40 to -$3.00; FY2027 -$3.30) while keeping a “Buy” rating and $50 price target. The large downward revisions signal higher expected cash burn or slower progress on clinical/commercial milestones, which is a clear near-term negative for valuation and could pressure the stock despite the buy rating. HC Wainwright Issues Pessimistic Forecast for Evommune (NYSE:EVMN) Stock Price
• Negative Sentiment: Additional outlets reported Clear Str/other firms’ upgrades (e.g., Zacks/TickerReport) but these are outweighed by the magnitude of HC Wainwright’s downward EPS revisions; the net effect today appears to be defensive selling and profit-taking. TickerReport coverage of Clear Str upgrade

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.